ReviewFrontiers in pharmacology2020
The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Antibiotics for the Treatment of Patients with Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections.Antibiotics (Basel, Switzerland) · 2025Review
- An Update on the Nutritional and Therapeutic Potential ofFood science & nutrition · 2025Review
- Unlocking the pharmacological potential of Brennnesselwurzel (Urtica dioica L.): an in-depth study on multifaceted biological activities.BMC complementary medicine and therapies · 2024Article
- The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- FOXA2 attenuates lipopolysaccharide‑induced pneumonia by inhibiting the inflammatory response, oxidative stress and apoptosis through blocking of p38/STAT3 signaling.Experimental and therapeutic medicine · 2023Article
- Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.European journal of medical research · 2023Review
- A comprehensive review on traditional uses, phytochemistry and pharmacological properties of Paeonia emodi Wall. ex Royle: current landscape and future perspectives.Chinese medicine · 2023Review
- Review
- Making a chink in their armor: Current and next-generation antimicrobial strategies against the bacterial cell envelope.Advances in microbial physiology · 2023Article
- Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis.Progress in biomaterials · 2022Review
- NovelPharmaceutics · 2022Article
- Eryngium caeruleum: an update on ethnobotany, phytochemistry and biomedical applications.Chinese medicine · 2022Review
- Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection.Nature communications · 2022Article
- Anticancer Potential and Other Pharmacological Properties ofPlants (Basel, Switzerland) · 2022Review
- New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.Antimicrobial agents and chemotherapy · 2022Article
- Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales.Microbial drug resistance (Larchmont, N.Y.) · 2022Article
- In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Nutraceutical Profiling, Bioactive Composition, and Biological Applications ofOxidative medicine and cellular longevity · 2022Review
- The Pharmacological Activities ofOxidative medicine and cellular longevity · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.